APA (7th ed.) Citation

C, D., M, M., A, C., R, L., B, B., S, B., . . . S, B. (2025). Sibiriline, a novel dual inhibitor of necroptosis and ferroptosis, prevents RIPK1 kinase activity and (phospho)lipid peroxidation as a potential therapeutic strategy. Cell death discovery, 11(1), 552. https://doi.org/10.1038/s41420-025-02852-8

Chicago Style (17th ed.) Citation

C, Delehouzé, et al. "Sibiriline, a Novel Dual Inhibitor of Necroptosis and Ferroptosis, Prevents RIPK1 Kinase Activity and (phospho)lipid Peroxidation as a Potential Therapeutic Strategy." Cell Death Discovery 11, no. 1 (2025): 552. https://doi.org/10.1038/s41420-025-02852-8.

MLA (9th ed.) Citation

C, Delehouzé, et al. "Sibiriline, a Novel Dual Inhibitor of Necroptosis and Ferroptosis, Prevents RIPK1 Kinase Activity and (phospho)lipid Peroxidation as a Potential Therapeutic Strategy." Cell Death Discovery, vol. 11, no. 1, 2025, p. 552, https://doi.org/10.1038/s41420-025-02852-8.